CTCBIO Inc (060590) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of CTCBIO Inc KRW 2,982, price KRW 3,005, upside -0.8%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch CTCBIO Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 2,700 KRW – 14,740 KRW · fair‑value band 2,337 KRW – 3,727 KRW · the 3,005 KRW price screens above the 2,982 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow CTCBIO in your weekly email
Every Wednesday you see whether CTCBIO is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products.
Show more
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diabetes, anti-inflammatory and arthritis, and harmones, as well as CTC covid-19 IgM/IgG combo test, a quick antibody test kit on covid-19. In addition, the company offers coating base/plasticizer/pore former, diluting agents, bonding agents, disintegrating agents, lubricants, solubilizer/biopharma, topicals, APIs, and food/health functional foods, as well as animal drugs, physiological activators, functional enhancers, and disinfectants. CTCBIO Inc. was founded in 1993 and is headquartered in Hwaseong-si, South Korea.
Stock analysis
CTCBIO Inc (060590) currently trades at 3,005 KRW, while our model-based Fair Value estimate is 2,982 KRW, implying the stock looks roughly 0.8% fairly valued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 3,311 KRW per share, and 13 of the 22 models we run sit above the 3,005 KRW price.
Bear case: the Earnings-Based group reads lowest at 1,373 KRW, and 9 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: 2,337 KRW (bear) to 3,727 KRW (bull), the price of 3,005 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
CTCBIO Inc reported revenue of 124B KRW in FY2025 versus 140B KRW in FY2021, a compound −3.1%/yr. Reported net income was 3.2B KRW in FY2025.
Key figures
Market cap 71.8B KRW (≈ $52.8M) · P/S ratio 0.54 · Net margin 2.6% · Return on equity 7.9% · Return on assets (EBIT) −1.5% · Operating margin 13.4% · Revenue (TTM) 129B KRW · Revenue growth (YoY) +16.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 57% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −1%, 060590 screens cheaper than that median.
Fair Value models
Bear 2,337 KRWFair Value 2,982 KRWBull 3,727 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−14.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.0%
Start year 2020 (pandemic). Over 10 years: +0.4% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−21.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−21.7%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 5%
⚠ Revenue per share shrinking 3.3%/yr over ~7Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +12.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 7/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score59 · Top 25%
Fair Value upside−1% · Above median
Profitability
Return on equity (TTM)8% · Top 25%
Return on assets4% · Top 25%
Net margin (TTM)5% · Below median
Operating margin (TTM)13% · Above median
Growth and dividend
Revenue growth17% · Above median
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CTCBIO Inc Fair Value". https://www.fairvalue-calculator.com/stock/060590
Frequently asked questions
Is CTCBIO Inc (060590) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2,982 KRW versus a price of 3,005 KRW, about −1% upside (fairly valued).
What is the fair value of 060590?
Our model-based fair value for CTCBIO Inc is 2,982 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,005 KRW.
What is the quality score of 060590?
CTCBIO Inc has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CTCBIO Inc (060590)?
Our model-based price target is the fair value of 2,982 KRW (as of Sep 24, 2026) from 22 valuation models. Cautious scenario 2,337 KRW, optimistic scenario 3,727 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the CTCBIO Inc stock forecast for 2026?
Our models put fair value at 2,982 KRW, about −1% upside versus a price of 3,005 KRW (fairly valued). Cautious scenario 2,337 KRW, optimistic scenario 3,727 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CTCBIO Inc (060590)?
CTCBIO Inc reported trailing-twelve-month revenue of about 129B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into CTCBIO Inc (060590)?
For today's price to be fair in a discounted-cash-flow model, CTCBIO Inc would have to grow free cash flow by +15.2 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 060590 use?
Our models discount CTCBIO Inc at 10.1 %: a base by market capitalisation (nano), country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CTCBIO Inc that is +15.2 % per year a year over ten years, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has CTCBIO Inc (060590) delivered so far?
Over the past 5 years revenue at CTCBIO Inc grew -1.0 % a year. The price currently implies +15.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CTCBIO Inc (060590) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into CTCBIO Inc (+15.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CTCBIO Inc (060590)?
The free-cash-flow yield on the price is 4.81 %: that much free cash flow CTCBIO Inc produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CTCBIO Inc (060590)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CTCBIO Inc it is 2,982 KRW per share (as of Sep 24, 2026), against a price of 3,005 KRW. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is CTCBIO Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 060590 trades above its calculated fair value: price 3,005 KRW, fair value 2,982 KRW, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 060590?
No. The price is what the market pays today (3,005 KRW); the fair value is what the company's own numbers justify (2,982 KRW). For CTCBIO Inc the two are 23.20 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CTCBIO Inc worth?
The market values CTCBIO Inc at about 71.8B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,005 KRW; our models calculate a fair value of 2,982 KRW per share.
What do the bullish and bearish scenarios say about 060590?
Our models span a range for CTCBIO Inc: cautious scenario 2,337 KRW, base 2,982 KRW, optimistic 3,727 KRW per share (as of Sep 24, 2026, price 3,005 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CTCBIO Inc (060590)?
Balance-sheet figures for CTCBIO Inc (as of Sep 24, 2026): return on equity 7.9%, debt of 0.13 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 060590 from its 52-week high?
CTCBIO Inc trades at 3,005 KRW, about 57% below its 52-week high of 7,060 KRW and 11% above the low of 2,700 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 2,982 KRW is for.
Which stocks are comparable to CTCBIO Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CTCBIO Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 3,005 KRW, calculated fair value 2,982 KRW (−1%), Quality Score 59/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 060590 calculated?
We run CTCBIO Inc through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2,982 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. CTCBIO Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CTCBIO Inc (060590)?
The closing price on Sep 23, 2026 was 3,005 KRW. Our model-based fair value is 2,982 KRW, about −1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CTCBIO Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of CTCBIO Inc
How large is the market capitalisation of CTCBIO Inc (060590)?
The market capitalisation of CTCBIO Inc is 71.8B KRW (≈ $52.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CTCBIO Inc (060590)?
The price-to-sales ratio of CTCBIO Inc is 0.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of CTCBIO Inc (060590)?
The net margin of CTCBIO Inc is 2.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CTCBIO Inc (060590)?
The return on equity (ROE) of CTCBIO Inc is 7.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CTCBIO Inc (060590)?
On an EBIT basis the return on assets of CTCBIO Inc is −1.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CTCBIO Inc (060590)?
The operating margin of CTCBIO Inc is 13.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CTCBIO Inc (060590)?
Revenue at CTCBIO Inc is growing +16.9% versus a year earlier (3y avg −9.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CTCBIO Inc (060590)?
Earnings per share at CTCBIO Inc are growing +463% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does CTCBIO Inc (060590) carry?
The net debt of CTCBIO Inc is 18.9B KRW (fiscal year 2025, ≈ 5.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CTCBIO Inc in the live analysis
One click puts CTCBIO Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
